MedTrace Logo

Subarachnoid Bupivacaine in Obese Patients Undergoing Cesarean Delivery

NCT04205344 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-12-23

No results posted yet for this study

Summary

This study evaluates the effect of subarachnoid hyperbaric bupivacaine on mean arterial blood pressure (MAP) of pregnant patients with obesity undergoing cesarean section half of the patients will receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg while the other half will receive a dose of 10 mg

Conditions

  • Anesthesia, Obstetrical

Interventions

DRUG

Bupivacaine 5 mg

Receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg

DRUG

Bupivacaine 10 mg

Receive subarachnoid hyperbaric bupivacaine at a dose of 10 mg

Sponsors & Collaborators

  • Hospital Civil de Guadalajara

    lead OTHER

Principal Investigators

  • MARIA DE LOS ANGELES CAMPECHANO ASCENCIO, MSc · Hospital Civil de Guadalajara

  • MIRIAM MENDEZ DEL VILLAR, MSc PhD · CENTRO UNIVERSITARIO DE TONALA

  • LEONEL GARCIA BENAVIDES · Hospital Civil de Guadalajara

  • JORGE BRAVO RUBIO · Hospital Civil de Guadalajara

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2017-06-30
Completion
2018-05-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04205344 on ClinicalTrials.gov